Balancing Weight Loss and Sarcopenia in Elderly Patients With Peripheral Artery Disease

Damianos G. Kokkinidis, MD, MSc; Ehrin J. Armstrong, MD, MSc; Jay Giri, MD, MPH

The estimated prevalence of peripheral artery disease (PAD) in the United States is between 8 and 12 million.\(^1\,^2\) PAD is associated with a 3- to 6-fold increase in cardiovascular morbidity and mortality risk.\(^3\) Although only one third of affected patients have typical claudication symptoms at the time of diagnosis, up to 20% undergo an amputation within 10 years.\(^1\,^3\,^5\) Individuals with PAD have higher risk for functional decline and impaired health-related quality of life (HRQOL) secondary to their ambulatory limitations. Even among patients traditionally labeled as having “asymptomatic PAD,” exertional leg symptoms often exist and limit functional status and HRQOL. Functional status in PAD can be assessed with objective measures such as treadmill testing, 6-minute walk distance (6MWD), and the Short Physical Performance Battery.\(^6\) However, these objective measures do not address a patient’s perception of ambulatory status or HRQOL, for which questionnaires are needed. Such questionnaires focus either on walking ability and its relationship with HRQOL, or they are broader with the goal of addressing a patient’s overall well-being and life satisfaction.\(^7\)

In this issue of the *Journal of the American Heart Association* (JAHA), Polonsky et al studied the association between weight changes and changes in calf muscle characteristics, knee strength, and walking ability in patients with PAD.\(^8\) For this purpose they retrospectively identified 389 (mean age 74.5±7.8) participants from the WALCS II (Walking and Leg Circulation Study II) with a mean follow-up of 3.23±1.37 years. In total, 42.2% of the patients were overweight, and 30.8% obese. Walking ability was assessed with an annual 6-minute walk test, and calf muscle characteristics were examined with computed tomography at baseline and at 2- and 4-year follow-up. After asking patients about weight changes, the investigators confirmed their responses with actual measurements. Weight change (loss or gain) was defined as a ≥5-lb change compared to the previous year’s visit. Patients’ self-report of weight loss (≥5 lb) was confirmed by measurements in roughly half of the person-years (52%). Patients who had lost weight but did not self-report weight loss were classified as having had unintentional weight loss. This allowed for creation of 4 groups for longitudinal analysis: stable weight; weight gain; intentional weight loss; and unintentional weight loss. Patients who experienced both weight gain and loss in different annual follow-up visits were excluded from the longitudinal analysis.

The authors found that intentional weight loss was associated with significantly less decline in the annual 6MWD compared to unintentional weight loss (intentional +3.7±18.2 m versus −20.8±10.45 m for unintentional weight loss; \(P<0.022\)) or weight gain (intentional +3.7±18.2 m versus weight loss −28.5±9.35; \(P=0.003\)), as well as numerically less decline compared to patients with stable weight (−14.0±4.3; \(P=0.067\)). Intentional weight loss was also associated with a greater reduction in calf muscle area compared to the stable-weight or weight-gain groups (\(P<0.001\)). There were no associated differences between the intentional weight-loss group and the other groups for other examined functional outcomes (isometric knee-extension strength and knee-extension power). Apart from weight change, other variables associated with the annual change in the 6MWD were the previous year’s 6MWD, age, male gender, smoking, and body mass index.

In summary, the authors discovered that intentional weight loss was associated with improved functional capacity as measured by 6MWD. However, there was a potential trade-off,
as these same patients actually lost greater amounts of calf muscle mass over time than patients with stable weight or weight gain as measured by computed tomography. These findings should be viewed in their context. First, the authors used a resampling analysis strategy in order to deal with patients who changed from having weight loss or weight gain to stable weight in their annual visits. Analyzing the data with person-years was probably the wisest option given the annual visits and weight measurements, but it also had the effect of camouflaging the modest number of patients in each group. The most important findings related to the intentional-weight-loss group, but analyses regarding this group contained data on only 19 to 43 person-years. Thus, it is likely that the difference observed in the 6MWD was largely driven by only a few patients. Also, only outcomes that can be examined with objective measures were used for the longitudinal analysis. Questionnaires about HRQOL may be equally effective ways to monitor functional status while also providing important data regarding patients’ perception of their health and well-being.7

How should the findings of this study change the practice of physicians involved in PAD care? The current study raises some important questions about the safety of intentional weight loss, specifically in elderly PAD patients. Weight-reduction strategies in overweight or obese nonelderly patients with PAD reduce overall cardiovascular risk while they also improve functional outcomes and HRQOL.9 But how does weight reduction affect the elderly, in whom the linkage between weight loss and sarcopenia can be a major issue? Sarcopenia, defined as the loss of lean muscle mass with aging, is especially prevalent in elderly individuals who experience unintentional weight loss. Patients with sarcopenia can be further stratified to sarcopenic-lean and sarcopenic-obese.10 There is major overlap in terms of etiology, symptoms, negative outcomes, and overall prognosis between sarcopenia and frailty.11–14 Frailty is defined as the syndrome of physiological decline in late life that is associated with increased vulnerability to adverse health outcomes. Frail patients have a higher risk for falls, hospitalizations, worse outcomes after percutaneous procedures or surgeries, disability, and death.15 Unintentional weight loss is included in frailty risk scores as an independent predictor of frailty, but weight loss—even when intentional—is also a risk factor for other frailty score components such as weakness, exhaustion, and sarcopenia. So should fear of sarcopenia and frailty lead us to alter our recommendations regarding weight loss to elderly patients with PAD? Randomized clinical trials (although not in the PAD population) in elderly patients with obesity have shown that weight loss is not associated with negative outcomes and can even decrease mortality when achieved through careful dietary instructions (adequate intake of protein of high biological quality, calcium, vitamin D) and carefully structured physical activity interventions.16–18 It is certainly possible that not all weight-loss strategies are created equal.

Similar to other difficult-to-answer questions in contemporary clinical medicine, the dilemma of balancing weight loss and the risk for sarcopenia/frailty has complicated answers. Given the absence of any risk scores that can weigh risk and benefits, each patient’s treatment strategy should be assessed individually. Involvement of a multidisciplinary group of providers including primary care physicians, cardiologists, endocrinologists, interventionists, dieticians, nutritionists, and physiotherapists can likely achieve the best outcomes by emphasizing an early focus on weight reduction without compromising an elderly patient’s muscle mass, bone health, and overall HRQOL. Cardiologists are familiar with the “heart team” concept that was built in order to achieve the best outcomes for coronary and structural heart disease, and recently there has been considerably greater emphasis on multidisciplinary care for patients with critical limb ischaemia.19 Contrary to the previously mentioned dilemmas, this last question probably has an easy answer: why should we wait for PAD patients to reach the critical limb ischemia stage before we manage their disease with a more holistic and multidisciplinary approach?

Disclosures

Dr Armstrong is a consultant to Abbott Vascular, Boston Scientific, Cardiovascular Systems, Gore, Intact Vascular, Janssen, Medtronic, and Philips. Dr Giri has served on advisory boards for AstraZeneca and has received research funds to his Institution from Recor Medical and St. Jude Medical. Dr Kokkinidis has no disclosures to report.

References

1. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324.
2. Hirsch AT, Haskal ZJ, Hertzler NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puscheck JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LMJ, White CJ, White J, White RA, Antman EM, Smith SCi, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47:1239–1312.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386.
4. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–1264.
5. Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabrisit RR, Criqui MH. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32:328–333.

6. de Liefde II, Hoeks SE, van Gestel YRBM, Klein J, Bax JJ, Verhagen HJM, van Domburg RT, Poldermans D. The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:482–487.

7. Nehler MR, McDermott MM, Treat-Jacobson D, Chetter I, Regensteiner JG. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med. 2003;8:115–126.

8. Polonsky TS, Tian L, Zhang D, Bazzano LA, Criqui MH, Ferrucci L, Guralnik JM, Kibbe MR, Leeuwenburgh C, Sufit RL, McDermott MM. Associations of weight change with changes in calf muscle characteristics and functional decline in peripheral artery disease. J Am Heart Assoc. 2019;8:e010890. DOI: 10.1161/JAHA.118.010890.

9. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai PJ, Razak F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–1649.

10. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–763.

11. Woo J, Yu R, Wong M, Yeung F, Wong M, Lum C. Frailty screening in the community using the FRAIL scale. J Am Med Dir Assoc. 2015;16:412–419.

12. Reijnierse EM, Trappenburg MC, Blauw GJ, Verlaan S, de van der Schuren MAE, Meskers CGM, Maier AB. Common ground? The concordance of sarcopenia and frailty definitions. J Am Med Dir Assoc. 2016;17:371.e7–12.

13. Yoshimura Y, Uchida K, Jeong S, Yamaga M. Effects of nutritional supplements on muscle mass and activities of daily living in elderly rehabilitation patients with decreased muscle mass: a randomized controlled trial. J Nutr Health Aging. 2016;20:185–191.

14. Fougere B, Vellas B, van Kan GA, Cesari M. Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia. Transl Neurosci. 2015;6:103–110.

15. Martin GP, Sperrin M, Ludman PF, de Belder MA, Redwood SR, Townend JN, Gunnng M, Moat NE, Banning AP, Buchan I, Mamas MA. Novel United Kingdom prognostic model for 30-day mortality following transcatheter aortic valve implantation. Heart. 2018;104:1109–1116.

16. Shea MK, Houston DK, Nicklas BJ, Messier SP, Davis CC, Miller ME, Harris TB, Kitzman DW, Kennedy K, Kritchevsky SB. The effect of randomization to weight loss on total mortality in older overweight and obese adults: the ADAPT Study. J Gerontol A Biol Sci Med Sci. 2010;65:519–525.

17. Shea MK, Nicklas BJ, Houston DK, Miller ME, Davis CC, Kitzman DW, Espeland MA, Appel LJ, Kritchevsky SB. The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized controlled weight-loss trial. Am J Clin Nutr. 2011;94:839–846.

18. Li Z, Heber D. Sarcopenic obesity in the elderly and strategies for weight management. Nutr Rev. 2012;70:57–64.

19. Armstrong EJ, Alam S, Henao S, Lee AC, DeRubertis BG, Montero-Baker M, Mena C, Gua B, Palena LM, Kovach R, Chandra V, AlMahameed A, Walker CM. Multidisciplinary care for critical limb ischemia: current gaps and opportunities for improvement. J Endovasc Ther. 2019;26:199–212.

Key Words: Editorials • exercise • obesity • peripheral artery disease